Advance Online
A teen smiles for a camera while the doctor sands behind her.
Advance Online

Enbrel Approved for Pediatric Psoriasis

FDA’s decision is the first approval of a biologic for use in pediatric psoriasis.

For the first time, the U.S. Food and Drug Administration (FDA) has approved a biologic medication for the treatment of pediatric plaque psoriasis.

On Nov. 4, 2016, the FDA approved Enbrel (etanercept) for the treatment of chronic moderate to severe plaque psoriasis in children ages 4 to 17.

One of the earliest biologics on the market, Enbrel has been approved for the treatment of psoriasis in adults since 2004. It is an injectable medication that works by lowering the activity of a protein known as tumor necrosis factor-alpha.

The protein, called a cytokine, is released by the immune system to trigger inflammation.

Even though Enbrel is new to pediatric psoriasis, it’s been used for more than a decade to treat children with juvenile idiopathic arthritis, according to Enbrel’s website.

It has also been investigated as potential medication for pediatric psoriasis for several years.

A study published in February 2016 in the Journal of the American Academy of Dermatology tested the long-term effects of Enbrel as a treatment for children with psoriasis. According to the results of the study, which involved almost 70 children ranging in age from 4 to 17, Enbrel stayed safe and effective for up to five years.

The most common adverse events experienced by children in the study included headache, upper respiratory tract infection and the common cold, as reported in the study.

Enbrel is manufactured by Amgen.

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.